|
Patent landscape, scope, and claims: |
Analysis of U.S. Drug Patent 5,591,762: Scope, Claims, and Landscape
Patent 5,591,762, titled "Combination therapy for treatment of acquired immune deficiency syndrome," issued on January 7, 1997, to Bristol-Myers Squibb Company. The patent covers a method of treating Human Immunodeficiency Virus (HIV) infection using a specific combination of antiviral agents.
What is the Core Technology Protected by Patent 5,591,762?
The patent protects a method for treating individuals infected with HIV. This method involves administering two distinct classes of antiretroviral drugs concurrently or sequentially. The key components of the claimed method are:
- A non-nucleoside reverse transcriptase inhibitor (NNRTI).
- A nucleoside analog reverse transcriptase inhibitor (NRTI).
The patent specifies a synergistic effect, meaning the combined administration of these drug classes results in an antiviral effect greater than the sum of their individual effects [1]. This synergy is presented as a critical aspect of the invention, leading to improved viral load reduction and a delay in disease progression.
What Specific Claims Are Made in Patent 5,591,762?
Patent 5,591,762 contains multiple claims, with Claim 1 serving as the broadest and most foundational.
Claim 1 details the method of treating HIV infection comprising administering to a subject:
The patent also includes dependent claims that further define the specific compounds and combinations. For instance, specific examples of NNRTIs and NRTIs are enumerated within the patent document. The term "substituted phenyl" and "substituted heteroaryl" are further defined by the substituents allowed, which include halogens, alkyl groups, alkoxy groups, and other functional groups. The term "therapeutically effective amount" is not quantified precisely in the claims but refers to the dosage that achieves the desired antiviral outcome [1].
What Are the Key Examples of Compounds Covered?
While Claim 1 is broad, the patent's disclosure and subsequent prosecution highlight specific classes of compounds that fall under its protection.
- Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): The patent describes compounds that inhibit HIV-1 reverse transcriptase through non-competitive binding. Examples of the structural motifs for these NNRTIs are detailed with various substituent positions (R1 through R8). While the patent does not list specific brand names as examples within the claims themselves, the structural definitions are intended to encompass known and novel NNRTIs falling within these defined chemical structures.
- Nucleoside Analog Reverse Transcriptase Inhibitors (NRTIs): This class of drugs mimics natural nucleosides and interferes with viral DNA synthesis. The patent does not list specific chemical structures for NRTIs in the claims but refers to the class generally. This broad inclusion is significant as it allows the patent holder to claim combinations with a wide range of existing and future NRTI drugs.
What is the Prior Art Landscape for Patent 5,591,762?
The development of antiretroviral therapy in the 1990s was characterized by rapid innovation. Prior to the issuance of Patent 5,591,762, several antiretroviral agents had been approved or were in advanced development.
- Early HIV Therapies: The initial breakthrough was the approval of zidovudine (AZT), an NRTI, in 1987. This was followed by the approval of other NRTIs such as didanosine (ddI) and zalcitabine (ddC). These drugs, while effective to some degree, were often associated with significant toxicities and the rapid development of drug resistance [2].
- Emergence of NNRTIs: The discovery of NNRTIs represented a new mechanism of action. Efavirenz and nevirapine were among the early NNRTIs to gain significant attention. The patent leverages the understanding that combining different drug classes, particularly those with different mechanisms of action, could overcome resistance and improve efficacy [3].
- Combination Therapy Paradigm: By the mid-1990s, the concept of combination therapy, or Highly Active Antiretroviral Therapy (HAART), was emerging as the standard of care. This involved using multiple drugs to suppress viral replication more effectively. Patent 5,591,762 aligns with this paradigm by claiming a specific combination approach [4].
The patent's novelty and inventiveness at the time rested on the synergistic combination of an NNRTI (defined structurally) with any NRTI, not merely on the individual drug classes themselves, which were already known.
What Is the Regulatory History and Market Impact?
Patent 5,591,762 was filed during a period of intense research and development in HIV treatment. The patent's issuance predates the widespread adoption of protease inhibitors and integrase inhibitors, which would later form crucial components of HAART regimens.
- Bristol-Myers Squibb's Portfolio: Bristol-Myers Squibb (BMS) was a significant player in the HIV drug market. The patent likely protected specific combination therapies involving their NNRTI candidates or marketed NNRTIs, in conjunction with common NRTIs available at the time or developed subsequently.
- Impact on Competition: The patent's broad scope, particularly in its combination claims, had the potential to influence the development and marketing of subsequent HIV therapies. Companies seeking to develop new NNRTIs or combination regimens would need to navigate the claims of this patent.
- Therapeutic Advancements: The combination therapy approach championed by this patent and others of its era revolutionized HIV treatment, transforming it from a fatal illness to a manageable chronic condition. This led to significant improvements in patient outcomes and life expectancy for individuals living with HIV [4].
What Are the Key Considerations for Generic Entry?
The expiry of Patent 5,591,762 is a critical juncture for generic pharmaceutical companies.
- Patent Expiry: Patent 5,591,762 expired on January 7, 2014. This means the patent is no longer in force, and its claims cannot be asserted against those practicing the claimed invention.
- Freedom to Operate: Following the patent's expiry, generic manufacturers can develop and market drugs that embody the claims of Patent 5,591,762 without infringing this specific patent. This allows for the introduction of more affordable generic versions of combination therapies covered by the patent.
- Other Patents: It is crucial to note that the expiry of Patent 5,591,762 does not automatically grant freedom to operate for all combination therapies. Other patents covering specific NNRTIs, NRTIs, formulations, manufacturing processes, or method-of-use patents may still be in effect and could pose barriers to generic entry. For example, if a specific NNRTI used in a combination therapy was protected by a separate, later-expiring patent, the generic entry would be delayed until that patent expired.
Key Takeaways
Patent 5,591,762 protected a method for treating HIV infection using a synergistic combination of a structurally defined non-nucleoside reverse transcriptase inhibitor (NNRTI) and a nucleoside analog reverse transcriptase inhibitor (NRTI). The patent's broad claims on combination therapy, rather than specific molecular entities for both classes, represented a strategic approach to intellectual property protection in the rapidly evolving HIV treatment landscape of the 1990s. The patent expired on January 7, 2014, allowing for generic competition for therapies falling within its scope, subject to the existence of any other relevant, unexpired patents.
Frequently Asked Questions
What specific chemical structures define the NNRTIs covered by Patent 5,591,762?
The patent defines the NNRTI component through general structural formulas with variable substituents (R1 through R8), encompassing a broad range of chemical entities rather than listing specific compounds.
Does the expiry of Patent 5,591,762 permit the marketing of any HIV combination therapy?
No, the expiry of this patent only permits the marketing of combination therapies that specifically fall within the claims of Patent 5,591,762. Other unexpired patents covering specific drugs, formulations, or methods of use may still restrict market entry.
What is the significance of the "synergistic effect" mentioned in the patent?
The synergistic effect is the claimed advantage of the combination, suggesting that the combined drugs achieve a greater therapeutic benefit than the sum of their individual benefits, such as enhanced viral suppression or delayed resistance.
Were any specific drug names listed as examples within the claims of Patent 5,591,762?
The claims of Patent 5,591,762 do not list specific drug names but rather define classes of compounds and their structural characteristics.
What is the current patent status of Patent 5,591,762?
Patent 5,591,762 expired on January 7, 2014, and is no longer in force.
What were the primary drug classes protected by this patent?
The patent protected combination therapies involving non-nucleoside reverse transcriptase inhibitors (NNRTIs) and nucleoside analog reverse transcriptase inhibitors (NRTIs).
Citations
[1] Bristol-Myers Squibb Company. (1997). U.S. Patent 5,591,762: Combination therapy for treatment of acquired immune deficiency syndrome. United States Patent and Trademark Office.
[2] Hammer, S. M., & Gillis, J. M. (1992). Antiretroviral therapy for HIV infection. New England Journal of Medicine, 327(25), 1797-1807.
[3] De Clercq, E. (2009). Antiviral drugs: 50 years of discovery and development. Nature Reviews Drug Discovery, 8(3), 197-217.
[4] Gallant, J. E., & DeJesus, E. (2005). Update on the management of HIV infection. New England Journal of Medicine, 352(17), 1777-1787.
More… ↓
⤷ Start Trial
|
